Q1 2026 Fennec Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Fennec Pharmaceuticals Inc (FENC) reported a 73% year-over-year increase in net product sales for the first quarter of 2026, reaching $15.1 million.
- The company has successfully expanded its commercial team, increasing its reach and frequency in the market, which has contributed to significant growth in new patient enrollments.
- Fennec HEARS, the company's full-service patient support program, has shown strong performance with a 48% quarter-over-quarter increase in completed infusions.
- The company is seeing positive early indicators from its Project Ignite initiative, which has expanded its ability to engage healthcare professionals and support adoption.
- Fennec Pharmaceuticals Inc (FENC) has announced multiple investigator-initiated studies to evaluate PEDMARK in new patient populations, indicating growing clinical interest and potential for broader adoption.
- Operating expenses increased by approximately $6 million year-over-year, primarily due to expanded marketing investment and increased commercial headcount.
- The company does not anticipate receiving the German milestone payment from its partner, Norgine, which could impact expected revenue streams.
- Despite positive cash flow in the first quarter, Fennec Pharmaceuticals Inc (FENC) expects the second quarter ending cash to be lower due to collection cycles with customers.
- The pediatric market is growing at a slower pace compared to the AYA market, which may impact overall growth potential in that segment.
- There is a natural ramp period for productivity with the newly expanded sales force, which may delay the full realization of benefits from the increased commercial footprint.
Good morning, ladies and gentlemen, and welcome to the Fennec Pharmaceuticals' first quarter 2026 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade. Please begin.
Thank you, operator, and good morning, everyone. Thank you for joining us. We are pleased to host Fennec Pharmaceuticals' first quarter 2026 earnings conference call today, during which we will review our financial results as well as provide a general business update.
Joining me from Fennec this morning is our Chief Executive Officer and Board Member, Jeff Hackman. I am also pleased to welcome our Chief Commercial Officer, Terry Evans, who is joining our earnings call for the first time. Terry is a seasoned commercial and operations leader with a proven track record for delivering significant revenue growth and leading high-performing teams.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
